Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $61.77.

NTLA has been the subject of several research reports. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $73.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Evercore ISI upgraded shares of Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Thursday, June 27th. Finally, Truist Financial reiterated a "buy" rating and issued a $120.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company's stock, valued at $893,698.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock valued at $250,168,000 after purchasing an additional 746,263 shares in the last quarter. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 5.5% during the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company's stock valued at $259,514,000 after purchasing an additional 606,507 shares during the last quarter. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Opaleye Management Inc. grew its stake in Intellia Therapeutics by 157.6% in the first quarter. Opaleye Management Inc. now owns 255,000 shares of the company's stock valued at $7,015,000 after purchasing an additional 156,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after purchasing an additional 98,865 shares during the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NTLA traded up $0.41 during mid-day trading on Tuesday, hitting $21.08. The company's stock had a trading volume of 1,543,191 shares, compared to its average volume of 1,540,554. The stock's 50-day moving average is $21.02 and its two-hundred day moving average is $22.89. The firm has a market capitalization of $2.03 billion, a PE ratio of -3.93 and a beta of 1.76. Intellia Therapeutics has a one year low of $17.09 and a one year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts' expectations of $19.68 million. During the same period in the previous year, the business posted ($1.40) earnings per share. Intellia Therapeutics's revenue for the quarter was down 48.5% on a year-over-year basis. Analysts expect that Intellia Therapeutics will post -5.22 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.